- AU$206.36m
- AU$169.56m
- AU$387.35m
Annual income statement for Mayne Pharma, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
R2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | 2026 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 158 | 190 | 395 | 413 | 387 |
| Cost of Revenue | |||||
| Gross Profit | 75.2 | 90.4 | 226 | 252 | 252 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Operating Interest Expense / Income | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 303 | 460 | 586 | 496 | 352 |
| Operating Profit | -146 | -270 | -190 | -83.3 | 35.8 |
| Net Income Before Taxes | -146 | -270 | -190 | -83.3 | 35.8 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -220 | -317 | -169 | -90.1 | 31.2 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -281 | 117 | -174 | -93.8 | 24.5 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | -281 | 117 | -174 | -93.8 | 24.5 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.9 | -3.19 | -1.83 | -1.03 | 0.629 |
| Special Dividends per Share |